slas2013 drug repurposing sig meeting
DESCRIPTION
Can target-based drug discovery be reconciled with phenotypic assays in the context of drug repurposing? One of the questions discussed at the SLAS Drug Repurposing SIG meeting at SLAS2013.TRANSCRIPT
11 © 2009 PerkinElmer© 2009 PerkinElmer© 2009 PerkinElmer
Best Strategies to Undertake a Drug Repurposing Initiative
22
Objectives
Can target-based drug discovery be reconciled with phenotypic assays in the context of drug repurposing?What are the best practices in assay design?How should compounds be tackled?
33
Attrition rates by phase
The Productivity Crisis in Pharmaceutical R&D, Fabio Pammolli, Laura Magazzini and Massimo Riccaboni, Nature Reviews Drug Discovery 2011 (10) 428-438.
44
How were new medicines discovered? David C. Swinney and Jason AnthonyNature Reviews - Drug Discovery, vol.10 p507 2011
Phenotypic vs Target Based R&D
55
Phenotypic vs Target Based R&D
How were new medicines discovered? David C. Swinney and Jason AnthonyNature Reviews - Drug Discovery, vol.10 p507 2011
66
19/20th century(serendipity, RDD)
20/21st century(technology, industrialization)
now what?
Phenotypic vs Target Based R&D
then!
77
Drug Discovery Processes
TargetID & Val
LeadDiscovery
LeadOptimization
CandidateDevelopment
Drug
Drug
In cellulo/vitro testing
In vivo testing
MechanisticStudy
Traditional:“target-driven”
Reverse Pharmacology: “Phenotypic”
88
Phenotypic vs Target Based R&D
Target Based• Compatible with both small
molecules and biologics• Controlled environment
Simplistic / “one-dimensional” avoid off-target artifacts robustness and reproducibility
• Molecular mechanism of action Pharmacodynamics studies
(Kd, Ki, etc)• Well suited for:
Intractable targets (eg. lipid kinases) Fragment-based screening
Phenotypic• Compatible with both small molecules
and biologics• Complex environment
“Black-box”/ multifactorial In-vivo / In vitro platforms Multiple targets & interactions
• Molecular mechanism of action Pharmacokinetics / ADMET
functional studies• Well suited for:
Drug repositioning / repurposing
99
“Target-based Shotgun” characterization: in vitro/cellulo molecular signature
1010
In cellulo / vivo molecule signatures
1111
Reconciling phenotypic and target-driven observations
30% o f 400 compounds profiled show new beneficial biologyUp to 90% of new indications are driven by “on-target” activitiesBiology is complex and there is a tremendous amount that is not understoodPhenotypic screening provides an opportunity to identify new clinically relevant uses of existing molecules driven by action on known molecular targets
Lipinski - Arrowhead SFO 2012
side vs off target effects?
1212
Success stories: Melior Pharmaceuticals (CRO)
1313
Success stories: Lilly / USC Partnership